How Today s Developments in the Treatment of Non-Small Cell Lung Cancer Will Change Tomorrow s Standards of Care
|
|
- Kory Allison
- 5 years ago
- Views:
Transcription
1 How Today s Developments in the Treatment of Non-Small Cell Lung Cancer Will Change Tomorrow s Standards of Care Mark G. Kris Memorial Sloan-Kettering Cancer Center, New York, New York, USA Key Words. NSCLC EGFR Adjuvant Neoadjuvant Docetaxel Gefitinib Bevacizumab Erlotinib Learning Objectives After completing this course, the reader will be able to: 1. Discuss the current status of adjuvant therapy in NSCLC. 2. Articulate the developing rate of targeted agents in the treatment of NSCLC. 3. Describe how tumor molecular biology may impact response to novel treatment. CME Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com Abstract Cisplatin (Platinol ; Bristol-Myers Squibb, Princeton, NJ, and carboplatin (Paraplatin ; Bristol-Myers Squibb), together with newer chemotherapies, such as docetaxel (Taxotere ; Aventis Pharmaceuticals Inc., Bridgewater, NJ, aventispharma-us.com), paclitaxel (Taxol ; Bristol- Myers Squibb), vinorelbine (Navelbine ; GlaxoSmith- Kline, Philadelphia, pemetrexed (Alimta ; Eli Lilly and Company, Indianapolis, and gemcitabine (Gemzar ; Eli Lilly and Company), have improved treatment outcomes in both advanced non-small cell lung cancer (NSCLC) and in the adjuvant/neoadjuvant setting. Newer systemic treatments for NSCLC, used in advanced stage IV management, are beginning to be studied in earlier stages of the disease, when treatment is better tolerated and potentially curative. Hopefully, newer agents with proven efficacies in advanced disease will enhance curability. Following the successful addition of bevacizumab (Avastin ; Genentech, Inc., South San Francisco, CA, to carboplatin/paclitaxel in advanced disease, bevacizumab is now being incorporated into adjuvant and neoadjuvant trials. Trials in stage IB IIIA patients will study neoadjuvant docetaxel/cisplatin/bevacizumab. The discovery that patients with exon 19 and 21 mutations in the epidermal growth factor receptor gene EGFR have around an 80% response rate to gefitinib (Iressa ; AstraZeneca Pharmaceuticals, Wilmington, DE, and that this response confers survival benefit indicates its potential utility for mutation-positive patients with advanced- and earlierstage disease. Clinical characteristics, such as never smoking status and adenocarcinoma, and especially bronchioloalveolar carcinoma histological features, can also identify individuals likely to respond to EGFR tyrosine kinase inhibitors. Studies of neoadjuvant erlotinib (Tarceva ; OSI Pharmaceuticals, Inc., Melville, NY, in operable NSCLC are planned. One such study includes cisplatin and docetaxel. Effective development of active agents and disease management based on molecular profiling of lung tumors will change tomorrow s standard of care. The Oncologist 2005;10(suppl 2):23 29 Correspondence: Mark G. Kris, M.D., Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA. Telephone: ; Fax: Received September 5, 2005; accepted for publication September 5, AlphaMed Press /2005/$12.00/0 The Oncologist 2005;10(suppl 2):
2 24 Developments in Treating NSCLC Introduction Table 1. Non-small cell lung cancer chemotherapy: In both advanced disease and in the adjuvant setting, progress is being made in non-small cell lung cancer (NSCLC) rate survival survival Response 1-year 2-year treatment. Newer agents added to our treatment armamentarium over the past 2 3 decades include the taxanes docetaxel (Taxotere ; Aventis Pharmaceuticals Inc., Bridgewater, NJ, and paclitaxel (Taxol ; Bristol-Myers Squibb, Princeton, NJ, the vinca alkaloid vinorelbine No chemotherapy Active single agent Active two-drug combination 0% 15% 25% 10% 20% 35% 0% 10% 20% (Navelbine ; GlaxoSmithKline, Philadelphia, Active three-drug gsk.com), and the nucleoside analogue gemcitabine (Gemzar combination 35% 35% 20% ; Eli Lilly and Company, Indianapolis, com). One-year survival rates in patients with advanced NSCLC have increased from around 10% without chemotherapy, to 20% with an active single agent, and to 35% with and after the 1995 meta-analysis. Table 2. Non-small cell lung cancer adjuvant trials including the combination of two active drugs (Table 1) [1 8]. Trial Survival In the adjuvant setting, a meta-analysis published 10 No. of 5 year years ago (involving 1,396 patients in eight trials) suggested patients (%) HR 95% CI p value the benefit of cisplatin (Platinol ; Bristol-Myers Squibb)- based chemotherapy [1]. There was clear evidence of better survival among patients having surgery plus cisplatin-based chemotherapy when compared with patients having surgery alone. At 5 years, the survival rates were 45% and 40%, respectively, an absolute difference of 5% and a very substantial increase in the proportion of patients alive. At 5 years, the extent of benefit surpassed that seen by Bonadonna et al. [9] using adjuvant cyclophosphamide/methotrexate/5-fluorouracil Meta-analysis [1] Italian Study [10] International [11] Canadian trial [12] U.S. study [13] 1,394 1,209 1, yr < (CMF) in breast cancer. Since 1995, four trials of adjuvant chemotherapy in NSCLC (from Italy, Canada, and the U.S., plus an international Abbreviations: 5 year (%), absolute increase in overall survival at 5 years for patients receiving adjuvant therapy (4-year survival date for U.S. study); CI, confidence interval; HR, hazard ratio. trial) have continued to suggest benefits in outcome (Table 2) [10 13]. Although some patients had stage I and II disease, the majority had stage III disease (mediastinal spread or spread to locoregional nodes). These studies are consistent with each other and with the degree of benefit suggested by the 1995 meta-analysis. The overall hazard ratio is around 0.87; and there is evidence that these trials (unlike the data from the meta-analysis) are changing clinical practice. These data provide the basis for combined modality therapy with the agents introduced in the 1990s [14 17]. At the Memorial Sloan-Kettering Cancer Center (MSKCC), it is now routine for patients with completely resected stage IB IIIA NSCLC to be referred for adjuvant treatment. Bevacizumab to Enhance Curability In the National Cancer Institute sponsored Eastern Cooperative Oncology Group (ECOG) 4599 phase III study, 878 stage IIIB/IV patients with no prior therapy were randomized to receive either carboplatin (Paraplatin ; Bristol- Myers Squibb)/paclitaxel chemotherapy alone or chemotherapy plus bevacizumab (Avastin ; Genentech, Inc., South San Francisco, CA, at a dose of 15 mg/kg. An interim analysis of that study showed that the median survival in the arm containing bevacizumab was 12.5 months, while the median survival in control patients given carboplatin/paclitaxel alone was 10.2 months [18]. That study changed our standard of care for stage IIIB and IV patients and challenged us to extend the benefits of this regimen into the adjuvant and neoadjuvant settings. Neoadjuvant studies offer vital opportunities for in vivo sensitivity testing, providing ample time to permit molecular profiling that can facilitate both cure and research. The Bevacizumab and Chemotherapy for Operable NSCLC (BEACON) trial, recently opened at MSKCC, involves stage IB IIIA patients with resectable NSCLC. It makes a distinction between nonsquamous, noncentral tumors on the one hand and tumors that are either squamous or large and central and on the other. Patients with nonsquamous peripheral tumors receive two cycles of docetaxel (75 mg/m 2 ) plus cisplatin (75 mg/m 2 ) plus
3 Kris 25 bevacizumab (15 mg/kg) every 3 weeks. Those with squamous or central tumors have the same chemotherapy but no bevacizumab (Fig. 1). Patients with a 10% or greater reduction in tumor by World Health Organization (WHO) criteria receive a further two cycles. The remainder are removed from the study. Patients who continue in the trial undergo surgical resection 4 weeks after the last cycle of chemotherapy. Bevacizumab is not administered with the final cycle of chemotherapy. Postoperatively, patients receive maintenance bevacizumab (15 mg/kg every 3 weeks) for 1 year. In early bevacizumab trials, patients with squamous tumors tended to have the greatest benefit from treatment but were also at greatest risk of hemoptysis. The hemoptysis does not appear to be an adverse effect affecting clotting mechanisms but rather a result of bevacizumab-induced disintegration of tumor. Following surgical removal of the primary lesions, patients with squamous tumors may be able to benefit from use of the a vascular endothelial growth factor antibody to attack microscopic residual disease remaining after surgery and neoadjuvant chemotherapy. Targeting the Epidermal Growth Factor Receptor Gene EGFR Between 1997 and 2002, 140 patients at MSKCC received single-agent gefitinib (Iressa ; AstraZeneca Pharmaceuticals, Wilmington, DE, [19]. There were partial responses in 21 patients (15%). Univariate analysis showed that the probability of a response was greater in never-smokers than in smokers (36% versus 8%; p <.001), greater in patients with adenocarcinoma than in those with other histologies (21% versus 0%; p <.001), and greater in bronchioloalveolar than in other adenocarcinomas (37% versus 15%; p <.001). A multivariate analysis showed highly significant differences between never smokers and others (p =.005) and between those with bronchioloalveolar carcinoma (BAC) and those with other adenocarcinomas (p =.007). Exon 19 Deletion and Exon 21 Point Mutations in EGFR The discovery that patients responsive to gefitinib have mutations in the ATP-binding site of the EGFR tyrosine kinase domain has opened up exciting possibilities. Several researchers have now studied gefitinib specifically in NSCLC patients with EGFR mutations. In a total of 86 such patients reported in the literature at this time (Table 3), 73 had a partial or complete response, giving the extraordinarily high response rate of 85% (ranging between 76% and 92% among the eight studies) [20 27]. As response has been shown to confer survival benefit, this is a major advance for the 10,000 or so U.S. patients with the mutation (and the thousands in Japan, Korea, and Taiwan). Han et al. [27] in Korea compared the survival of gefitinib-treated patients with wild-type EGFR with that of patients with mutated EGFR. Patients with EGFR mutations had a median survival time of 31 months, compared with 7 months for patients with wild-type EGFR (p <.001). KRAS Mutations For evolutionary reasons, EGFR and KRAS mutations tend to be mutually exclusive. Pao et al. [22] have produced evidence that KRAS mutations confer primary resistance to both gefitinib and erlotinib (Tarceva ; OSI Pharmaceuticals, Inc., Melville, NY, In our series, 17 Table 3. Partial responses with gefitinib in non-small cell lung cancer: results in patients with epidermal growth factor receptor gene (EGFR) mutations No. No. with Response Study treated PR/CR rate Figure 1. Summary of treatment schema of the Bevacizumab and Chemotherapy for Operable NSCLC trial. Abbreviations: CT, computed tomography; NSCLC, non-small cell lung cancer; POD, progression of disease; q3 weeks, every 3 weeks; WHO, World Health Organization. Lynch et al. [20] % Paez et al. [21] % Pao et al. [22] % Huang et al. [23] % Mitsudomi et al. [24] % Cortes-Funes et al. [25] % Tokumo et al. [26] % Han et al. [27] % Total % (76% 92%) Abbreviations: CR, complete response; PR, partial response.
4 26 Developments in Treating NSCLC of 22 patients with EGFR mutations were sensitive to either gefitinib or erlotinib. None of the patients with KRAS mutations were sensitive. This research has permitted us to identify some groups of patients for treatment with EGFR tyrosine kinase inhibitors. Those with an EGFR mutation but not a KRAS mutation have a high likelihood of response to either gefitinib or erlotinib. Those negative for both mutations are indeterminate. Those positive for a KRAS mutation and negative for the EGFR mutation should be considered for an alternative agent. Clinical Surrogates for EGFR Mutation Testing At present, analysis of EGFR mutations appears to be the most promising means of predicting sensitivity to EGFR tyrosine kinase inhibitors; however, clinical surrogates for the mutation have been identified. The literature suggests a strong correlation between never smoking and response to gefitinib or erlotinib (Table 4) [19, 27 32]. Of patients who have never smoked, between 18% and 63% respond to the EGFR tyrosine kinase inhibitors. In current or former smokers, the range is 4% 18%. Two huge, randomized, placebo-controlled, studies showed a clear survival advantage in never smokers treated with EGFR-inhibiting agents (Table 5) [32, 33]. In the Iressa Survival Evaluation in Lung Cancer (ISEL) trial, Table 4. Smoking history and sensitivity to epidermal growth factor receptor gene (EGFR) tyrosine kinase inhibitors Response Response rate, rate, Agent never- current/former Study (trial) smokers smokers Difference Miller et al. Gefitinib [19] (MSKCC) 36% 8% 28% Cohen et al. Gefitinib [28] (IDEAL2) 29% 5% 24% Fukuoka et al. Gefitinib [29] (Japan) 33% 9% 24% Takano et al. Gefitinib [30] (Japan) 63% 18% 45% Han et al. Gefitinib [27] (Korea) 33% 15% 18% Shepherd et al. Erlotinib [31] (BR.21) 25% 4% 21% Tamura et al. Gefitinib [32] (ISEL) 18% 5% 13% Abbreviations: BR.21, National Cancer Institute of Canada Clinical Trials Group BR.21 trial; IDEAL2, Iressa Dose Evaluation in Advanced Lung Cancer 2; ISEL, Iressa Evaluation in Lung Cancer; MSKCC, Memorial Sloan-Kettering Cancer Center. the hazard ratio for gefitinib versus placebo was 0.67, and it was 0.42 in the National Cancer Institute of Canada Clinical Trials Group BR.21 trial of erlotinib versus placebo. The incidence of EGFR mutation in NSCLC patients who never smoked ranges from 26% in Korea [27] to 68% in Japan [34], and consistently is far higher than in patients with a smoking history. The likelihood of EGFR mutation also relates to extent of smoking, at around 50% in those with 10 pack-years and less and 0% in those with more than 75 pack-years [35]. Trials adding an EGFR tyrosine kinase inhibitor to chemotherapy for nonselected patients were negative on all survival end points. However, the Tarceva Responses in Conjunction with Paclitaxel and Carboplatin (TRIBUTE) trial incorporated a prospective analysis of the effect of adding erlotinib to chemotherapy in never-smokers [36]. In that group, the median survival in patients given erlotinib plus chemotherapy was 23 months, compared with 10 months in patients receiving placebo plus chemotherapy. Based on these data, we are routinely recommending initial treatment with both erlotinib and chemotherapy to never smokers with advanced NSCLC. A Cancer and Leukemia Group B (CALGB) trial will randomize patients with a minimal smoking history (a group that represents around 20% of all cases) to erlotinib alone or erlotinib plus chemotherapy to confirm and extend the TRIBUTE observations. Patients with adenocarcinoma with BAC features (a histology found in up to one fourth of NSCLC cases) are also more likely to be sensitive to EGFR agents and again are likely to have relevant mutations [37]. A multicenter phase II trial of erlotinib in patients with BAC produced response rates of 45% in patients who had never smoked and 18% in smokers [38]. Table 5. Patients treated in placebo-controlled trials of gefitinib or erlotinib: survival improvement in patients who had never smoked Number of Hazard Trial Regimens never-smokers ratio (year) compared (% of total) (95% CI) ISEL [32] Gefitinib versus placebo (22%) ( ) BR.21 [33] Erlotinib versus placebo (20%) ( ) Abbreviations: BR.21, National Cancer Institute of Canada Clinical Trials Group BR 21 trial; CI, confidence interval; ISEL, Iressa Evaluation in Lung Cancer.
5 Kris 27 These findings have also prompted a neoadjuvant trial of erlotinib in association with docetaxel and cisplatin (Fig. 2). Proof of Principle Trial Investigators at MSKCC are now conducting a proof of principle trial to test the hypothesis that a radiographic response to gefitinib in NSCLC correlates with the presence of an EGFR mutation (Trial ). In this study, stage I or II patients with adenocarcinomas with BAC features or who have smoked fewer than 10 pack-years and have measurable lesions on a chest computed tomography (CT) scan will have a core needle biopsy for assessment of KRAS and EGFR mutation, pretreatment (Fig. 3). They then will receive gefitinib (250 mg) for at least 21 days, followed by a repeat CT scan. At surgery, tumor specimens will be banked, and EGFR and KRAS mutation status will be again assayed if no Figure 2. Study design of the Erlotinib and Chemotherapy for Operable NSCLC trial. Abbreviations: BAC, bronchioloalveolar carcinoma; CT, computed tomography; NSCLC, nonsmall cell lung cancer; po, orally; POD, progression of disease; q3 weeks, every 3 weeks; WHO, World Health Organization. mutations were detected in the initial biopsy specimen. Following the operation, patients who have had at least a minor response by standard criteria by CT (established using a standard scan but specially developed software) or who have an EGFR mutation will continue to receive gefitinib as an adjuvant treatment. Several statistical hypotheses stand to be confirmed. First, in this enriched population, it is assumed that 25% of patients will have a radiographic response to gefitinib. Secondly, the expectation is that EGFR mutations will be present in 80% of those who respond radiographically to gefitinib but in only 10% of those who do not. An example of a response following gefitinib in a patient with an exon 19 deletion in EGFR is shown in Figure 4. Conclusions Efforts should be made to find and treat all patients who can benefit from the range of current therapies. This especially includes patients in need of adjuvant therapy, and those who could be helped by specific agents, such as those with EGFR mutations, who have a good chance of responding to gefitinib or erlotinib. Clinical leads can provide guidance valuable to bench research and vice versa. It is imperative to concentrate on strategies that improve survival, with the ultimate aim of achieving cure. As data become available, agents such as gefitinib, erlotinib, or bevacizumab should be added to potentially curative adjuvant and neoadjuvant treatments. Disclosure of Potential Conflicts of Interest Dr. Kris has acted as a consultant for and has received support from Eli Lilly, Genentech, GlaxoSmithKline, and Bristol-Myers Squibb. Figure 3. Epidermal growth factor receptor gene (EGFR) mutations and gefitinib sensitivity: MSKCC proof of principle trial (Trial ). Abbreviations: BAC, bronchioloalveolar carcinoma; CT, computed tomography; NSCLC, non-small cell lung cancer; po, orally. Figure 4. Computed tomography scan response of a patient with an epidermal growth factor receptor gene (EGFR) exon 19 deletion.
6 28 Developments in Treating NSCLC References 1 Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311: Lynch TJ Jr. Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non-small cell lung cancer. Semin Oncol 2001;28(suppl 9): Kris MG. What does chemotherapy have to offer patients with advancedstage non-small cell lung cancer? Semin Oncol 1998;25(suppl 8): Shepherd FA, Dancey J, Ramlau R et al. A prospective randomized trial of docetaxel versus best supportive care in patients with non-smallcell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18: Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer study group. J Clin Oncol 2000;18: Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2001;20: Evans TL, Lynch TJ Jr. Lung cancer. The Oncologist 2001;6: Gandara R, Chansky K, Gaspar LE et al. Long term survival in stage IIIb non-small cell lung cancer (NSCLC) treated with consolidation docetaxel following concurrent chemoradiotherapy (SWOG S9504). J Clin Oncol 2005;23:7059a. 9 Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332: Scagliotti GV, Fossati R, Torri V et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-smallcell lung cancer. J Natl Cancer Inst 2003;95: Arriagada R, Bergman B, Dunant A et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350: Winton TL, Livingston R, Johnson D et al. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10. J Clin Oncol 2004;22(suppl 14): Strauss GM, Herndon J, Maddaus MA et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol J Clin Oncol 2004;22(suppl 14): Rosell R, Felip E. Role of multimodality treatment for lung cancer. Semin Surg Oncol 2000;18: Rosell R.New approaches in the adjuvant and neoadjuvant therapy of non-small cell lung cancer, including docetaxel (Taxotere) combinations. Semin Oncol 1999;26(suppl 11): Mattson K, Ten Velde G, Krofta K et al. Early results of an international phase III study evaluating Taxotere as neo-adjuvant therapy for radically-treatable stage III NSCLC. Lung Cancer 2000;29(suppl 1): Mattson KV, Abratt RP, Ten Velde G et al. Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study. Ann Oncol 2003;14: Tyagi P. Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced nonsmall-cell lung cancer: preliminary results from the ECOG 4599 trial. Clin Lung Cancer 2005;6: Miller VA, Kris MG, Shah N et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22: Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004;350: Epub 2004 Apr Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: Pao W, Miller VA. Epidermal growth factor receptor mutations, smallmolecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23: Huang SF, Liu HP, Li LH et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10: Mitsudomi T, Kosaka T, Endoh H et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23: Cortes-Funes H, Gomez C, Rosell R et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-smallcell lung cancer patients. Ann Oncol 2005;16: Tokumo M, Toyooka S, Kiura K et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in nonsmall cell lung cancers. Clin Cancer Res 2005;11: Han SW, Kim TY, Hwang PG et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in nonsmall-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23: Cohen MH, Williams GA, Sridhara R et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. The Oncologist 2003;8: Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21: Takano T, Ohe Y, Sakamoto H et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; [Epub ahead of print]. 31 Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353: Tamura K, Fukuoka M. Gefitinib in non-small cell lung cancer. Expert Opin Pharmacother 2005;6: Fuster LM, Sandler AB. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes. Clin Lung Cancer 2004;6(suppl 1):S24 S Kosaka T, Yatabe Y, Endoh H et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:
7 Kris Pham D, Kris MG, McDonough T et al. Estimation of the likelihood of epidermal growth factor receptor (EGFR) mutations based on cigarette smoking history in patients with adenocarcinoma of the lung. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, May 14 17, 2005:7069a. 36 Miller VA, Herbst R, Prager D et al. Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: sub-group analysis of TRIB- UTE. J Clin Oncol 2004;22(suppl 14):7061a. 37 Kris MG, Sandler A, Miller VA et al. EGFR and KRAS mutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a phase II multicenter trial. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, May 14 17, 2005:7029a. 38 Kris MG, Sandler A, Miller V et al. Cigarette smoking history predicts sensitivity to erlotinib: results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC). J Clin Oncol 2004;22(suppl 14):7062a.
CANCER TREATMENT REGIMENS
CANCER TREATMENT S Lung Cancer The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule and initiation
More informationRegulatory Issues - FDA
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Regulatory Issues - FDA FDA Drug Approval Summary: Erlotinib
More informationCâncer de Pulmão Não Pequenas Células
Câncer de Pulmão Não Pequenas Células Carboplatina + Paclitaxel Paclitaxel: 200mg/m 2 IV D1 Carboplatina: AUC 6 IV D1 a cada 21 dias X 4 ciclos Ref. (1) Vinorelbina + Cisplatina Vinorelbina: 25mg/m 2 IV
More informationEGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
102 Journal of Cancer Research Updates, 2012, 1, 102-107 EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence Kenichi
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationPRACTICE GUIDELINE SERIES
ELLIS et al. PRACTICE GUIDELINE SERIES The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent nonsmall-cell lung cancer: a Canadian
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationPlatinum-based doublets are considered to be the standard
Blackwell Publishing Asia Review Article Recent trends in the treatment of advanced lung cancer Nagahiro Saijo 1 National Cancer Center, Hospital East, Kashiwanoha 6-5-1, Kashiwa-shi, Chiba 277-8577, Japan
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationEGFR, Lung Cancer and Cytology. Maureen F. Zakowski, M.D. Lung cancer is one of the most lethal cancers in Western countries and in Japan.
EGFR, Lung Cancer and Cytology Maureen F. Zakowski, M.D. Lung cancer is one of the most lethal cancers in Western countries and in Japan. It is histopathologically divided into two major sub-groups: Small
More informationKey Words. Bevacizumab Avastin Nonsquamous Non-small cell lung cancer First-line Advanced/metastatic disease
The Oncologist Regulatory Issues: FDA FDA Drug Approval Summary: Bevacizumab (Avastin ) Plus Carboplatin and Paclitaxel as First-Line Treatment of Advanced/Metastatic Recurrent Nonsquamous Non-Small Cell
More informationKey Words. Epidermal growth factor receptor EGFR Tyrosine kinase inhibitor TKI Erlotinib Non-small cell lung cancer NSCLC Second-line therapy
The Oncologist Lung Cancer Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance? THOMAS E. STINCHCOMBE,MARK A. SOCINSKI Multidisciplinary Thoracic Oncology Program, Lineberger
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationSystemic therapy in early stage NSCLC. Disclosures
Systemic therapy in early stage NSCLC Christian Manegold, MD Professor of Medicine, Heidelberg University Interdisciplinary Thoracic Oncology Department of Surgery University Medical Center Mannheim, Germany
More informationNational Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer
Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer This technology summary is based on information available at the time of research and a limited
More informationKey Words. Erlotinib Non-small cell lung cancer Maintenance treatment
The Oncologist Regulatory Issues: FDA The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. Approval
More informationComparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC)
J Lung Cancer 2009;8(2):61-66 Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC) More effective treatments in first, second, and third-line of metastatic
More informationOncologist. The. Taxane-Platinum Combinations in Advanced Non-Small Cell Lung Cancer: A Review JAMES R. RIGAS LEARNING OBJECTIVES ABSTRACT
The Oncologist Taxane-Platinum Combinations in Advanced Non-Small Cell Lung Cancer: A Review JAMES R. RIGAS Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, New Hampshire, USA Key Words.
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationAuthor(s) Ohmatsu, Hironobu; Kubota, Kaoru; N. Citation Respiratory medicine (2010), 104(3)
Title Trends in chemotherapy for elderly non-small-cell lung cancer. Author(s) Kim, Young Hak; Yoh, Kiyotaka; Niho Ohmatsu, Hironobu; Kubota, Kaoru; N Citation Respiratory medicine (2010), 104(3) Issue
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationPrognosis of recurrent non small cell lung cancer following complete resection
1300 Prognosis of recurrent non small cell lung cancer following complete resection HIDEFUMI SASAKI, AYUMI SUZUKI, TSUTOMU TATEMATSU, MASAYUKI SHITARA, YU HIKOSAKA, KATSUHIRO OKUDA, SATORU MORIYAMA, MOTOKI
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 June 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 June 2012 TARCEVA 25 mg, film-coated tablet B/30 (CIP code: 369 232 3) TARCEVA 100 mg, film-coated tablet B/30 (CIP
More informationESMO Preceptorship Programme NSCLC Singapore 15 November 2017
ESMO Preceptorship Programme NSCLC Singapore 15 November 2017 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo-adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationLUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
More informationThe epidermal growth factor receptor (EGFR) is a promising
ORIGINAL ARTICLE Clinical Significance of Epidermal Growth Factor Receptor Gene Mutations on Treatment Outcome after First-line Cytotoxic Chemotherapy in Japanese Patients with Non-small Cell Lung Cancer
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationRESEARCH ARTICLE. Ryosuke Hirano 1, Junji Uchino 1 *, Miho Ueno 2, Masaki Fujita 1, Kentaro Watanabe 1. Abstract. Introduction
RESEARCH ARTICLE Low-dose Epidermal Growth Factor Receptor (EGFR)- Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body
More informationIRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca
IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The
More informationThere has been a growing interest in lung cancer in neversmokers,
ORIGINAL ARTICLE,, and Time of Diagnosis Are Important Factors for Prognosis Analysis of 1499 Never-Smokers with Advanced Non-small Cell Lung Cancer in Japan Tomoya Kawaguchi, MD,* Minoru Takada, MD,*
More informationLung cancer update 2007
Lung cancer update 2007 HARMESH R NAIK, MD. January 24, 2007 Epidemiology (world) Estimated 1.35 million new cases in world in 2002 Estimated 1.179 million deaths in world in 2002 Common cancer diagnosis
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationAdjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer
Review Article Adjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer Robert Pirker Department of Medicine I, Medical University of Vienna, Vienna, Austria Correspondence
More informationThe Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2015;47(4):638-644 Original Article http://dx.doi.org/10.4143/crt.2014.316 Open Access The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line
More informationChemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002
Chemo-radiotherapy in non-small cell lung cancer HARMESH R NAIK, MD. September 25, 2002 Epidemiology Estimated 170000 new cases Estimated 157,000 deaths Second commonest cancer diagnosis in men and women
More informationErlotinib (Tarceva ): A Brief Overview Donna Clay, RPh, Yvette M. Lipman, PharmD, and Mary Ellen Bonk, PharmD
Erlotinib (Tarceva ): A Brief Overview Donna Clay, RPh, Yvette M. Lipman, PharmD, and Mary Ellen Bonk, PharmD INTRODUCTION Lung cancer is the leading cause of death from cancer in the U.S. It was estimated
More informationThoracic Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Lung Cancer Salvage Therapy for Advanced Non-Small Cell Lung
More informationErlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More informationThe ABCs of BAC: Bronchioloalveolar Carcinoma
The ABCs of BAC: Bronchioloalveolar Carcinoma Howard (Jack) West, MD Medical Oncologist Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA March, 2009 President & CEO GRACE
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 NAVELBINE 20 mg, soft capsules B/1 (CIP: 365 948-4) NAVELBINE 30 mg, soft capsules B/1 (CIP: 365 949-0)
More informationPersonalized maintenance therapy in advanced non-small cell lung cancer
China Lung Cancer Research Highlight Personalized maintenance therapy in advanced non-small cell lung cancer Kazuhiro Asami, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi Department of Clinical Oncology,
More informationChemotherapy is the standard treatment of advanced nonsmall
ORIGINAL ARTICLE Third-Line Chemotherapy in Advanced Non-small Cell Lung Cancer: Identifying the Candidates for Routine Practice Nicolas Girard, MD,* Pascale Jacoulet, MD,* Marie Gainet, MD,* Rami Elleuch,
More informationGene-Expression Profiling and the Future of Adjuvant Therapy
Gene-Expression Profiling and the Future of Adjuvant Therapy Marc van de Vijver Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands Key Words. Gene-expression profiling Prognostic
More informationSystemic Treatment for Patients with Advanced Non-Small Cell Lung Cancer P.M. Ellis, E.T. Vella, Y.C. Ung and the Lung Cancer Disease Site Group
A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Systemic Treatment for Patients with Advanced Non-Small Cell Lung Cancer P.M. Ellis, E.T. Vella, Y.C. Ung and
More informationStrategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors
Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors Miklos Pless Medical Oncology Kantonsspital Winterthur 2 Setting the stage. 1995: Chemotherapy works! Meta-Analysis
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationSystemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions
Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions Suresh Ramalingam, a Chandra Belani b a Lung & Thoracic Malignancies Program, University of Pittsburgh
More informationResearch Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy
SAGE-Hindawi Access to Research Lung Cancer International Volume 2011, Article ID 152125, 4 pages doi:10.4061/2011/152125 Research Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients:
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationKey Words. Lung cancer EGFR Mutation Genetic screening
The Oncologist Lung Cancer Response to Treatment and Survival of Patients with Non-Small Cell Lung Cancer Undergoing Somatic EGFR Mutation Testing LECIA V. SEQUIST, VICTORIA A. JOSHI, PASI A. JÄNNE, ALONA
More informationLung cancer affects approximately 1.2 million people annually,
ORIGINAL ARTICLE Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer A Phase II Study Kaoru Kubota, MD, PhD, Yutaka Nishiwaki, MD, Tomohide Tamura,
More informationPrognostic Factors of Pathologic Stage IB Non-small Cell Lung Cancer
Ann Thorac Cardiovasc Surg 2011; 17: 58 62 Case Report Prognostic Factors of Pathologic Stage IB Non-small Cell Lung Cancer Motoki Yano, MD, Hidefumi Sasaki, MD, Satoru Moriyama, MD, Osamu Kawano MD, Yu
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationItalian clinical research in non-small-cell lung cancer
Annals of Oncology 16 (Supplement 4): iv110 iv115, 2005 doi:10.1093/annonc/mdi919 Italian clinical research in non-small-cell lung cancer C. Gridelli 1, A. Rossi 1, D. Galetta 2, P. Maione 1, C. Ferrara
More informationRetrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients
(2017) 1(1): 16-24 Mini Review Open Access Retrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients Chao Pui I 1,3, Cheng Gregory 1, Zhang Lunqing 2, Lo Iek
More informationEGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy?
Review Article EGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy? Robert Pirker Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria Corresponding
More informationOncologist. The. ASCO 2000: Critical Commentaries. Lung Cancer Highlights THOMAS J. LYNCH, JR. ABSTRACT
The Oncologist ASCO 2000: Critical Commentaries Lung Cancer Highlights THOMAS J. LYNCH, JR. Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA Key Words. Small cell lung cancer Non-small
More informationDavid S. Ettinger. The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Lung Cancer Clinical Implications of EGFR Expression in the Development
More informationINTRODUCTION. Key words: Gefitinib, EGFR-tyrosine kinase inhibitors, Non Small Cell Lung Cancer
Gefitinib (Iressa) in Non Small Cell Lung Cancer at Kuwait Cancer Control Centre Experience, Kuwait, with Focus on Future Use of EGFR- Tyrosine Kinase Inhibitors Vinay Vyas, Al-Awadi Shafika, Jarslov N,
More informationTargeted therapy in lung cancer : experience of NIO-RABAT
Targeted therapy in lung cancer : experience of NIO-RABAT I.ELGHISSASSI, H.ERRIHANI Medical oncology department, NIO- RABAT 02-05- 2012, FEZ In Morocco, lung cancer is the most common tumor among men At
More informationAdenocarcinoma of the lung is the leading cause of cancerrelated
ORIGINAL ARTICLE Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma Jenifer L. Marks, MD,* Stephen Broderick, MD, Qin Zhou, MA, Dhananjay Chitale, MD, Allan
More informationPage: 1 of 27. Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
Last Review Status/Date: December 2014 Page: 1 of 27 Non-Small-Cell Lung Cancer Description Over half of patients with non-small-cell lung cancer (NSCLC) present with advanced and therefore incurable disease,
More informationSystemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know)
Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know) นายแพทย ช ยย ทธ ย ทธ เจร ญธรรม หน วยมะเร งว ทยา ภาคว ชาอาย ร อาย รศาสตร Inter-hospitol Conference, 16 th March 2013 Systemic
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More informationA Clinical Context Report
Non-small Cell Lung Cancer in Practice An Expert Commentary With Karen Reckamp, MD A Clinical Context Report Clinical Context: NSCLC in Practice Expert Commentary Jointly Sponsored by: and Clinical Context:
More informationFrequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung
Journal of Cancer Therapy, 2014, 5, 1012-1020 Published Online September 2014 in SciRes. http://www.scirp.org/journal/jct http://dx.doi.org/10.4236/jct.2014.511106 Frequency of Epidermal Growth Factor
More informationSurvival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China Yu-Tao Liu, Xue-Zhi Hao, Jun-Ling Li, Xing-Sheng
More informationAHFS Final. line. Criteria Used in. combined. cisplatin. Strength. established was. Non-small Cell Lung. Cancer: of carboplatin and
Drug/Drug Combination: Cetuximab Off-label Use: First-line treatment of advanced non-small Use for Review: cell lung cancer Criteria Used in Selection of Off-labell AHFS Final Determination of Medical
More informationRESEARCH ARTICLE. EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Non-squamous Non-small Cell Lung Cancer
RESEARCH ARTICLE EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Non-squamous Non-small Cell Lung Cancer Satoshi Igawa 1 *, Yuichi Sato 2, Mikiko Ishihara 1, Masashi Kasajima
More informationSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
The Oncologist Mayo Clinic Hematology/Oncology Reviews Is There a Preferred Combination Chemotherapy Regimen for Metastastic Non-Small Cell Lung Cancer? DAVID S. ETTINGER Sidney Kimmel Comprehensive Cancer
More informationOriginal Article. Abstract
Japanese Journal of Clinical Oncology, 2015, 45(7) 670 676 doi: 10.1093/jjco/hyv054 Advance Access Publication Date: 15 April 2015 Original Article Original Article Efficacy of chemotherapy after first-line
More informationFirst line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die?
Perspective First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die? Jared Weiss Multidisciplinary Thoracic Oncology Program, Lineberger
More informationEli Lilly and Company Ltd
www.lilly.co.uk Eli Lilly and Company Limited Lilly House Priestley Road Basingstoke Hampshire RG24 9NL Medical and Product Information: +44 (0) 1256 315999 28 February 2007 Mr Christopher Feinmann Technology
More informationEpidermal Growth Factor Receptor (EGFR) Mutation Analysis for Patients with Non-Small Cell Lung Cancer (NSCLC) Original Policy Date
MP 2.04.34 Epidermal Growth Factor Receptor (EGFR) Mutation Analysis for Patients with Non-Small Cell Lung Cancer (NSCLC) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last
More informationTechnology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer Technology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227 NICE 2018. All rights reserved. Subject to
More informationGemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer
Clinical Medicine Insights: Oncology Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationTumor Board Discussions: Case 1
Tumor Board Discussions: Case 1 David S. Ettinger, MD The Alex Grass Professor of Oncology Johns Hopkins University School of Medicine Baltimore, Maryland Case #1 50-year-old Asian female, never smoker
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationNew Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management
New Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management Ramaswamy Govindan, MD Director Professor of Medicine Director, Thoracic Oncology Program Department
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationHistology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
More informationTo help doctors give their patients the best possible care, the American. What to Know
Patient Information Resources from ASCO What to Know ASCO s Guideline on Chemotherapy for Stage IV Non-Small Cell Lung Cancer SEPTEMBER 2011 KEY MESSAGES Chemotherapy for stage IV non-small cell lung cancer
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationLung cancer remains the leading cause of cancer-related
Original Article EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma Kosuke Tanaka, MD,* Toyoaki Hida, MD, PhD,* Yuko Oya, MD,* Tomoyo Oguri, MD,
More informationNCCN Non Small Cell Lung Cancer V Meeting July 8, 2016
NSCL 3 Submission from Myriad requesting the following statement to be listed as an additional high risk factor in footnote p : For lung ADC, a highrisk 46 gene molecular prognostic score determined by
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationAdditional clinical features of this patient include:
*Not an actual patient. Challenge your knowledge of biomarker testing in advanced NSCLC. Consider this case study of disease progression following chemotherapy, with insightful commentary from Dr Edward
More information